KR20240152826A - 신규한 오리스타틴 유사체 및 이의 면역접합체 - Google Patents
신규한 오리스타틴 유사체 및 이의 면역접합체 Download PDFInfo
- Publication number
- KR20240152826A KR20240152826A KR1020247023535A KR20247023535A KR20240152826A KR 20240152826 A KR20240152826 A KR 20240152826A KR 1020247023535 A KR1020247023535 A KR 1020247023535A KR 20247023535 A KR20247023535 A KR 20247023535A KR 20240152826 A KR20240152826 A KR 20240152826A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- structural formula
- immunoconjugate
- article
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163293583P | 2021-12-23 | 2021-12-23 | |
| US63/293,583 | 2021-12-23 | ||
| PCT/US2022/053738 WO2023122228A1 (en) | 2021-12-23 | 2022-12-21 | Novel auristatin analogs and immunoconjugates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240152826A true KR20240152826A (ko) | 2024-10-22 |
Family
ID=86903604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247023535A Pending KR20240152826A (ko) | 2021-12-23 | 2022-12-21 | 신규한 오리스타틴 유사체 및 이의 면역접합체 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250049937A1 (https=) |
| EP (1) | EP4453000A4 (https=) |
| JP (1) | JP2025500404A (https=) |
| KR (1) | KR20240152826A (https=) |
| CN (1) | CN118829645A (https=) |
| AU (1) | AU2022422015A1 (https=) |
| CA (1) | CA3241878A1 (https=) |
| IL (1) | IL313784A (https=) |
| TW (1) | TW202328162A (https=) |
| WO (1) | WO2023122228A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025067221A1 (zh) * | 2023-09-26 | 2025-04-03 | 上海齐鲁制药研究中心有限公司 | 奥瑞他汀衍生物及其抗体药物偶联物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015017552A1 (en) * | 2013-08-01 | 2015-02-05 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to cd37 proteins |
| CA2951368A1 (en) * | 2014-06-13 | 2015-12-17 | Novartis Ag | Auristatin derivatives and conjugates thereof |
| CA3205824A1 (en) * | 2014-10-09 | 2016-04-14 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
| US20190194315A1 (en) * | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
| CN119241554A (zh) * | 2017-12-15 | 2025-01-03 | 四川科伦博泰生物医药股份有限公司 | 生物活性物偶联物及其制备方法和用途 |
-
2022
- 2022-12-21 CA CA3241878A patent/CA3241878A1/en active Pending
- 2022-12-21 EP EP22912460.7A patent/EP4453000A4/en active Pending
- 2022-12-21 US US18/713,436 patent/US20250049937A1/en active Pending
- 2022-12-21 WO PCT/US2022/053738 patent/WO2023122228A1/en not_active Ceased
- 2022-12-21 KR KR1020247023535A patent/KR20240152826A/ko active Pending
- 2022-12-21 AU AU2022422015A patent/AU2022422015A1/en active Pending
- 2022-12-21 JP JP2024537875A patent/JP2025500404A/ja active Pending
- 2022-12-21 CN CN202280092301.4A patent/CN118829645A/zh active Pending
- 2022-12-21 IL IL313784A patent/IL313784A/en unknown
- 2022-12-22 TW TW111149562A patent/TW202328162A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL313784A (en) | 2024-08-01 |
| TW202328162A (zh) | 2023-07-16 |
| JP2025500404A (ja) | 2025-01-09 |
| WO2023122228A1 (en) | 2023-06-29 |
| US20250049937A1 (en) | 2025-02-13 |
| CN118829645A (zh) | 2024-10-22 |
| EP4453000A4 (en) | 2025-12-24 |
| EP4453000A1 (en) | 2024-10-30 |
| AU2022422015A1 (en) | 2024-07-04 |
| CA3241878A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020263231B2 (en) | Camptothecin derivatives | |
| JP2024038168A (ja) | 生物活性分子コンジュゲート、その調製法及び使用 | |
| TWI712605B (zh) | 含有ｃｔｉ藥效基團之雙功能性細胞毒性劑 | |
| WO2024059236A1 (en) | Novel camptothecin analogs and immunoconjugates thereof | |
| US20260027226A1 (en) | Antibody-drug conjugates | |
| JP2025518554A (ja) | リガンド薬物複合体及びその使用 | |
| KR20240152826A (ko) | 신규한 오리스타틴 유사체 및 이의 면역접합체 | |
| CA3198230A1 (en) | Conjugate and use thereof | |
| WO2025149667A1 (en) | Antibody drug conjugates and uses thereof | |
| IL312533A (en) | Novel auristatin analogs and immunoconjugates thereof | |
| CN119053607B (zh) | 喜树碱类化合物及其偶联物、其制备方法和用途 | |
| IL322216A (en) | Drug conjugates, methods for their preparation and use | |
| KR20250049520A (ko) | 인간 trop2에 대한 항체를 포함하는 항체-약물 접합체 및 이의 용도 | |
| HK40117241A (zh) | 新型澳瑞他汀类似物及其免疫偶联物 | |
| HK40115429A (zh) | 新型澳瑞他汀类似物及其免疫偶联物 | |
| CN118541378A (zh) | 新型澳瑞他汀类似物及其免疫偶联物 | |
| WO2025176733A1 (en) | Antibody-drug conjugates involving small molecule atr/chk1 inhibitors | |
| CA3137125C (en) | Camptothecin derivatives | |
| TW202608866A (zh) | 包含ｓｔｉｎｇ促效劑之抗體藥物結合物及其用途 | |
| WO2024193692A1 (zh) | 连接子及其在配体药物偶联物中的应用 | |
| HK40069519B (en) | Camptothecin derivatives | |
| HK40069519A (en) | Camptothecin derivatives | |
| HK1233252A1 (en) | Bifunctional cytotoxic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |